Literature DB >> 9743299

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

A M Wardley1, G C Jayson, D J Goldsmith, M C Venning, P Ackrill, J H Scarffe.   

Abstract

Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9743299      PMCID： PMC2062981          DOI： 10.1038/bjc.1998.577

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  13 in total

1.  Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

Authors:  M Skinner; J Anderson; R Simms; R Falk; M Wang; C Libbey; L A Jones; A S Cohen
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

2.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

3.  Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.

Authors:  D C Case; D J Lee; B D Clarkson
Journal:  Am J Med       Date:  1977-12       Impact factor: 4.965

4.  Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.

Authors:  G Merlini; E Ascari; N Amboldi; V Bellotti; E Arbustini; V Perfetti; M Ferrari; I Zorzoli; M G Marinone; P Garini
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Authors:  R L Comenzo; E Vosburgh; R W Simms; P Bergethon; D Sarnacki; K Finn; S Dubrey; D V Faller; D G Wright; R H Falk; M Skinner
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

6.  Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy.

Authors:  K Fielder; B G Durie
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

7.  Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.

Authors:  P N Hawkins; M J Myers; J P Lavender; M B Pepys
Journal:  Lancet       Date:  1988-06-25       Impact factor: 79.321

8.  [Treatment of AL amyloidosis without myeloma].

Authors:  Y Lévy; D Belghiti-Deprez; A Sobel
Journal:  Ann Med Interne (Paris)       Date:  1988

Review 9.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

10.  VAD chemotherapy as remission induction for multiple myeloma.

Authors:  H Anderson; J H Scarffe; M Ranson; R Young; G S Wieringa; G R Morgenstern; L Fitzsimmons; D Ryder
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640
View more
  4 in total

Review 1.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

2.  How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.

Authors:  Junichi Hoshino; Yoshifumi Ubara; Naoki Sawa; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Tatsuya Suwabe; Noriko Hayami; Masayuki Yamanouchi; Fumi Takemoto; Shuichi Taniguchi; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2011-03-09       Impact factor: 2.801

3.  Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report.

Authors:  Toshikazu Araoka; Hiroya Takeoka; Keisuke Nishioka; Masaki Ikeda; Makiko Kondo; Azusa Hoshina; Seiji Kishi; Makoto Araki; Rokuro Mimura; Taichi Murakami; Akira Mima; Kojiro Nagai; Hideharu Abe; Toshio Doi
Journal:  J Med Case Rep       Date:  2010-10-18

4.  Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.

Authors:  Osamu Yamazaki; Yoshifumi Ubara; Tatsuya Suwabe; Shohei Nakanishi; Junichi Hoshino; Naoki Sawa; Noriko Hayami; Masayuki Yamanouchi; Fumi Takemoto; Takaichi Kenmei; Kazuhiro Masuoka; Kenichi Oohashi
Journal:  Clin Exp Nephrol       Date:  2009-06-05       Impact factor: 2.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.